# Phase II Study of Aldesleukin (IL-2) Following the Administration of Zanolimumab (Anti-CD4mAb) in Metastatic Melanoma and Metastatic Renal Cancer

> **NCT01160445** · PHASE2 · TERMINATED · sponsor: **National Cancer Institute (NCI)** · enrollment: 9 (actual)

## Conditions studied

- Metastatic Melanoma
- Metastatic Renal Cancer

## Interventions

- **DRUG:** Zanolimumab
- **DRUG:** Aldesleukin

## Key facts

- **NCT ID:** NCT01160445
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2010-06
- **Primary completion:** 2012-01
- **Final completion:** 2012-01
- **Target enrollment:** 9 (ACTUAL)
- **Why stopped:** The study was terminated because we were not able to obtain the study drug.
- **Last updated:** 2015-10-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01160445

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01160445, "Phase II Study of Aldesleukin (IL-2) Following the Administration of Zanolimumab (Anti-CD4mAb) in Metastatic Melanoma and Metastatic Renal Cancer". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT01160445. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*